Moelis appoints new member to board of directors

Moelis and Company

Moelis & Company has announced the appointment of Dr. Yvonne Greenstreet as an independent member of the Board of Directors.

Dr. Greenstreet has over 20 years of experience in the pharmaceutical industry and has held senior roles in research and development, strategy, commercial development and portfolio management. She was formerly Senior Vice President and Head of Medicines Development for Pfizer where she was a member of the Specialty Business global executive team. Dr. Greenstreet also spent 18 years at GlaxoSmithKline, most recently as Senior Vice President and Chief of Strategy for Research and Development and a member of the corporate portfolio management board. She held a variety of positions at GlaxoSmithKline prior to this, including Chief Medical Officer for Europe.

Ken Moelis, Chairman and CEO of Moelis & Company, said, 'Yvonne’s wealth of experience in the pharmaceutical industry and her proven track record as a highly regarded business leader will greatly benefit our Firm and our clients. We are delighted to welcome her as Moelis & Company’s newest Board member'.

Dr. Greenstreet currently serves on the Board of Directors of Pacira Pharmaceuticals, a specialty pharmaceutical company focused on the development of products for postsurgical pain control, the Board of Directors of Advanced Accelerator Applications, a radiopharmaceutical company that develops diagnostic and therapeutic products, and the Board of Directors of Indivior, a pharmaceutical company that develops products to treat addiction. She is also a member of the Scientific Advisory Board of the Bill & Melinda Gates Foundation.

Dr. Greenstreet holds a Bachelor of Medicine, Bachelor of Surgery from the University of Leeds, United Kingdom, and an M.B.A. from INSEAD, France.

JefferiesAnd the Best Place to Work in the global financial markets 2016 is...

Register for Financial Markets News Alerts